Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Perou

Showing results (361-370 of 476) with videos related to

Pageof 48
Sort By:
Ebiomedicine|June 23, 2021
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapyNuria Chic, Francesco Schettini, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trialMaggie C U Cheang, K David Voduc, Dongsheng Tu, et al.
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell typesMatthew D Wilkerson, Xiaoying Yin, Katherine A Hoadley, et al.
Nature|August 30, 2000
Molecular portraits of human breast tumoursC M Perou, T Sørlie, M B Eisen, et al.
The Journal of Clinical Investigation|October 24, 2023
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Nature Communications|July 18, 2023
Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancerZhe Jiang, YoungJun Ju, Amjad Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Journal of the National Cancer Institute|September 2, 2017
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer StudyMelissa A Troester, Xuezheng Sun, Emma H Allott, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Pageof 48

Showing results (361-370 of 476) with videos related to

Sort By:
Pageof 48
Ebiomedicine|June 23, 2021
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapyNuria Chic, Francesco Schettini, Fara Brasó-Maristany, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trialMaggie C U Cheang, K David Voduc, Dongsheng Tu, et al.
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell typesMatthew D Wilkerson, Xiaoying Yin, Katherine A Hoadley, et al.
Nature|August 30, 2000
Molecular portraits of human breast tumoursC M Perou, T Sørlie, M B Eisen, et al.
The Journal of Clinical Investigation|October 24, 2023
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Nature Communications|July 18, 2023
Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancerZhe Jiang, YoungJun Ju, Amjad Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Journal of the National Cancer Institute|September 2, 2017
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer StudyMelissa A Troester, Xuezheng Sun, Emma H Allott, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Pageof 48